Additional sex combs-like (ASXL) proteins are mammalian homologues of additional sex combs (Asx), a regulator of trithorax and polycomb function in Drosophila. While there has been great interest in ASXL1 due to its frequent mutation in leukemia, little is known about its paralog ASXL2, which is frequently mutated in acute myeloid leukemia patients bearing the RUNX1-RUNX1T1 (AML1-ETO) fusion. Here we report that ASXL2 is required for normal haematopoiesis with distinct, non-overlapping effects from ASXL1 and acts as a haploinsufficient tumour suppressor. While Asxl2 was required for normal haematopoietic stem cell self-renewal, Asxl2 loss promoted AML1-ETO leukemogenesis. Moreover, ASXL2 target genes strongly overlapped with those of RUNX1 and AML1-ETO and ASXL2 loss was associated with increased chromatin accessibility at putative enhancers of key leukemogenic loci. These data reveal that Asxl2 is a critical regulator of haematopoiesis and mediates transcriptional effects that promote leukemogenesis driven by AML1-ETO.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454368 | PMC |
| http://dx.doi.org/10.1038/ncomms15429 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrative analysis of ASXL family genes reveals ASXL2 as an immunoregulatory molecule in head and neck squamous cell carcinoma.
Sci Rep
December 2024
Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, People's Republic of China.
Despite the progress in conventional treatments for head and neck squamous cell carcinoma (HNSCC), the 5-year survival rate remains below 70%. Enhancing immunotherapy outcomes through personalized treatment strategies, particularly by identifying immune-related biomarkers, is critical. The ASXL family are associated with malignancies, but their relationship with HNSCC has not been elucidated.
View Article and Find Full Text PDFASXLs binding to the PHD2/3 fingers of MLL4 provides a mechanism for the recruitment of BAP1 to active enhancers.
Nat Commun
June 2024
Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Article Synopsis
- MLL4 and MLL3 are proteins often mutated in cancer that modify histones, specifically monomethylating histone H3K4, and contain unexplored PHD finger domains.
- The PHD2 and PHD3 fingers of MLL4 and MLL3 interact with ASXL2, a component of the PR-DUB complex, which plays a role in regulating histone modifications.
- Analysis shows that the MLL3/4 and PR-DUB complexes work together in a way that relies on the binding of ASXL1/2, which is essential for recruiting the deubiquitinase BAP1 to active enhancers in embryonic stem cells.
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
Am J Hematol
July 2024
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
KAT6A::EP300 fusion in congenital myeloid sarcoma: Yet another novel molecular marker indicating spontaneous remission?: A case report.
Medicine (Baltimore)
July 2023
Department of Pediatrics, Division of Pediatric Hematology-Oncology, University Hospitals-Rainbow Babies and Children's Hospital, Cleveland Medical Center, Cleveland, OH.
Rationale: Acute myeloid leukemia (AML)/myeloid sarcoma (MS) is risk-stratified based on cytogenetics. Although most congenital AML/MS have a dismal prognosis, certain genetic variants such as t (8, 16) [KAT6A::cAMP response element-binding protein (CREB) - binding protein fusion] and more recently t (8, 22) [KAT6A::EP300 fusion] have shown spontaneous remissions. KAT6A located on chromosome 8p11 encodes KAT6A protein, a histone/lysine acetyltransferase enzyme.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!